Literature DB >> 12527894

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.

Ariane Freund1, Corine Chauveau, Jean-Paul Brouillet, Annick Lucas, Matthieu Lacroix, Anne Licznar, Françoise Vignon, Gwendal Lazennec.   

Abstract

Estrogen-receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors. Here, we demonstrate, that interleukin-8 (IL-8) was clearly overexpressed in most ER-negative breast, ovary cell lines and breast tumor samples tested, whereas no significant IL-8 level could be detected in ER-positive breast or ovarian cell lines. We have also cloned human IL-8 from ER-negative MDA-MB-231 cells, and we show that IL-8 produced by breast cancer cells is identical to monocyte-derived IL-8. Interestingly, the invasion potential of ER-negative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells by two fold, thus confirming the invasion-promoting role of IL-8. On the other hand, exogenous expression of estrogen receptors in ER-negative cells led to a decrease of IL-8 levels. In summary, our data show that IL-8 expression is negatively linked to ER status of breast and ovarian cancer cells. We also support the idea that IL-8 expression is associated with a higher invasiveness potential of cancer cells in vitro, which suggests that IL-8 could be a novel marker of tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527894      PMCID: PMC2034407          DOI: 10.1038/sj.onc.1206113

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.

Authors:  M D Balbay; C A Pettaway; H Kuniyasu; K Inoue; E Ramirez; E Li; I J Fidler; C P Dinney
Journal:  Clin Cancer Res       Date:  1999-04       Impact factor: 12.531

2.  NH2-terminal pentapeptide of endothelial interleukin 8 is responsible for the induction of apoptosis in leukemic cells and has an antitumor effect in vivo.

Authors:  Y Terui; H Tomizuka; Y Mishima; M Ikeda; T Kasahara; M Uwai; M Mori; T Itoh; M Tanaka; M Yamada; S Shimamura; Y Ishizaka; K Ozawa; K Hatake
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

3.  Interleukin 8: an autocrine growth factor for human ovarian cancer.

Authors:  L Xu; I J Fidler
Journal:  Oncol Res       Date:  2000       Impact factor: 5.574

4.  IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration.

Authors:  L F Lee; R P Hellendall; Y Wang; J S Haskill; N Mukaida; K Matsushima; J P Ting
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

5.  Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

Authors:  K Inoue; J W Slaton; B Y Eve; S J Kim; P Perrotte; M D Balbay; S Yano; M Bar-Eli; R Radinsky; C A Pettaway; C P Dinney
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

6.  Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  R W Veltri; M C Miller; G Zhao; A Ng; G M Marley; G L Wright; R L Vessella; D Ralph
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

7.  The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?

Authors:  K Ivarsson; E Runesson; K Sundfeldt; M Haeger; L Hedin; P O Janson; M Brännström
Journal:  Gynecol Oncol       Date:  1998-12       Impact factor: 5.482

8.  Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.

Authors:  P Pujol; J M Rey; P Nirde; P Roger; M Gastaldi; F Laffargue; H Rochefort; T Maudelonde
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

9.  Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.

Authors:  G Fontanini; D Campani; M Roncella; D Cecchetti; S Calvo; A Toniolo; F Basolo
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  84 in total

1.  CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.

Authors:  Gong Yang; Daniel G Rosen; Guangzhi Liu; Fan Yang; Xiaoqing Guo; Xue Xiao; Fengxia Xue; Imelda Mercado-Uribe; Jiaoti Huang; Sue-Hwa Lin; Gordon B Mills; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

2.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

3.  Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor.

Authors:  Jennifer L Halpern; Amy Kilbarger; Conor C Lynch
Journal:  Cancer Lett       Date:  2011-05-23       Impact factor: 8.679

4.  Interleukin 8 in progression of hormone-dependent early breast cancer.

Authors:  Jelena Milovanovic; Natasa Todorovic-Rakovic; Tijana Vujasinovic; Zaki Abu Rabi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

Review 5.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  Potential Indexing of the Invasiveness of Breast Cancer Cells by Mitochondrial Redox Ratios.

Authors:  Nannan Sun; He N Xu; Qingming Luo; Lin Z Li
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS).

Authors:  Frank He; Nora L Springer; Matthew A Whitman; Siddharth P Pathi; Yeonkyung Lee; Sunish Mohanan; Stephen Marcott; Aaron E Chiou; Bryant S Blank; Neil Iyengar; Patrick G Morris; Maxine Jochelson; Clifford A Hudis; Pragya Shah; Jennie A M R Kunitake; Lara A Estroff; Jan Lammerding; Claudia Fischbach
Journal:  Biomaterials       Date:  2019-09-11       Impact factor: 12.479

8.  Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.

Authors:  Kaouther Snoussi; Wijden Mahfoudh; Noureddine Bouaouina; Meriem Fekih; Hedi Khairi; Ahmed N Helal; Lotfi Chouchane
Journal:  BMC Cancer       Date:  2010-06-12       Impact factor: 4.430

9.  EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.

Authors:  Narendra V Sankpal; Timothy P Fleming; William E Gillanders
Journal:  Mol Cancer Res       Date:  2013-02-01       Impact factor: 5.852

Review 10.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.